A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma.

Trial Profile

A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Cyclophosphamide; Prednisone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms REPEAT
  • Most Recent Events

    • 19 Sep 2016 Efficacy and safety results published in the Blood.
    • 25 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 20 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top